Hsbc Holdings PLC Makes New Investment in Corcept Therapeutics Incorporated $CORT

Hsbc Holdings PLC purchased a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the first quarter, Holdings Channel reports. The fund purchased 6,653 shares of the biotechnology company’s stock, valued at approximately $265,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in CORT. Whittier Trust Co. grew its position in Corcept Therapeutics by 1,243.8% in the first quarter. Whittier Trust Co. now owns 5,402 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 5,000 shares in the last quarter. Simplify Asset Management Inc. bought a new position in Corcept Therapeutics in the first quarter valued at $1,522,000. Patten Group Inc. purchased a new stake in Corcept Therapeutics during the first quarter valued at about $519,000. Formidable Asset Management LLC raised its position in Corcept Therapeutics by 87.5% during the first quarter. Formidable Asset Management LLC now owns 11,681 shares of the biotechnology company’s stock valued at $471,000 after purchasing an additional 5,450 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in Corcept Therapeutics by 9.1% during the first quarter. Pictet Asset Management Holding SA now owns 15,689 shares of the biotechnology company’s stock worth $632,000 after purchasing an additional 1,309 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept’s latest quarterly results exceeded expectations, with earnings of $0.36 per share versus the $0.02 consensus estimate and revenue of $256.15 million versus $221.15 million expected. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
• Positive Sentiment: Piper Sandler assigned Corcept an “Overweight” rating, signaling confidence in the company’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $165 price target. The firm raised its FY2026 EPS forecast to $2.15 from $0.80 and increased its Q3 2026 estimate to $0.78 from $0.34, suggesting expectations for significant near-term earnings growth.
• Neutral Sentiment: Brokerages’ average target price is $94.67, materially below the recent $114.49 reference price. This gap indicates analysts have not fully caught up with the rally or see limited upside from current levels. Brokerages Set Corcept Therapeutics Target Price at $94.67
• Negative Sentiment: Despite the bullish rating, HC Wainwright reduced its FY2027 EPS forecast to $3.95 from $5.38 and lowered estimates for Q1–Q4 2027. These revisions raise concerns about the pace of longer-term earnings growth, particularly with CORT trading at a very high valuation.

Insider Buying and Selling

In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $88.35, for a total value of $2,208,750.00. Following the transaction, the insider directly owned 9,755 shares of the company’s stock, valued at $861,854.25. The trade was a 71.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $93.13, for a total value of $1,862,600.00. Following the completion of the transaction, the insider directly owned 3,985 shares in the company, valued at $371,123.05. This trade represents a 83.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 300,000 shares of company stock worth $22,088,050 in the last 90 days. 20.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a report on Monday, July 27th. Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday. Canaccord Genuity Group boosted their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday. UBS Group set a $135.00 target price on Corcept Therapeutics in a research note on Thursday, May 28th. Finally, Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $119.17.

Corcept Therapeutics Price Performance

Corcept Therapeutics stock opened at $114.49 on Monday. The firm has a fifty day simple moving average of $84.77 and a two-hundred day simple moving average of $56.91. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $122.21. The company has a market capitalization of $12.38 billion, a PE ratio of 272.60 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. The firm had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The company’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same period last year, the firm earned $0.29 earnings per share. As a group, equities analysts expect that Corcept Therapeutics Incorporated will post 1.13 earnings per share for the current fiscal year.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.